<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01340209</url>
  </required_header>
  <id_info>
    <org_study_id>205.464</org_study_id>
    <nct_id>NCT01340209</nct_id>
  </id_info>
  <brief_title>Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma</brief_title>
  <official_title>A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Safety and Efficacy of Tiotropium Inhalation Solution Delivered Via Respimat Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo Over 52 Weeks in Patients With Moderate to Severe Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of this trial is to evaluate the safety and efficacy of 2.5 and 5 µg tiotropium over
      a 52-week treatment period as compared to placebo. Tiotropium inhalation solution delivered
      by the Respimat inhaler will be examined on top of maintenance treatment with inhaled
      corticosteroid controller medication in patients with moderate to severe persistent asthma.
      Efficacy and safety will be assessed by measuring effects on lung function, effects on asthma
      exacerbations, effects on asthma control, and number of adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Drug-related Adverse Events</measure>
    <time_frame>after the first dose of trial medication and within 30 days after the last dose of trial medication, up to 409</time_frame>
    <description>The primary endpoint is the number of patients with drug-related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response</measure>
    <time_frame>baseline and week 52</time_frame>
    <description>Trough FEV1 response was defined as change from baseline at week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response</measure>
    <time_frame>baseline and week 52</time_frame>
    <description>Trough FVC response was defined as change from baseline at week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough PEF Response</measure>
    <time_frame>baseline and week 52</time_frame>
    <description>Trough PEF response was defined as change from baseline at week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean PEFam Response</measure>
    <time_frame>baseline and week 52</time_frame>
    <description>Weekly mean PEFam response was defined as change from baseline at week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean PEFpm Response</measure>
    <time_frame>baseline and week 52</time_frame>
    <description>Weekly mean PEFpm response was defined as change from baseline at week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean PEF Variability Response</measure>
    <time_frame>baseline and week 52</time_frame>
    <description>Weekly mean PEF variability response was defined as change from baseline at week 52.
The PEF variability is the absolute difference between morning and evening PEF value, divided by their mean, expressed as a percent. Response was defined as change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Number of Puffs of Rescue Medication During the Whole Day (Response)</measure>
    <time_frame>baseline and week 52</time_frame>
    <description>Response of weekly mean number of puffs of rescue medication during the whole day at week 52. Response was defined as change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Score of Asthma Symptoms in the Morning (Response)</measure>
    <time_frame>baseline and week 52</time_frame>
    <description>Response of weekly mean score of asthma symptoms in the morning at week 52. Response was defined as change from baseline.
5-point verbal rating scale, with answer 1 representing no impairment at all and answer 5 representing the greatest impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Score of Asthma Symptoms During the Day (Response)</measure>
    <time_frame>baseline and week 52</time_frame>
    <description>Response of weekly mean score of asthma symptoms during the day at week 52. Response was defined as change from baseline.
5-point verbal rating scale, with answer 1 representing no impairment at all and answer 5 representing the greatest impairment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">285</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Tiotropium Respimat (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tiotropium low dose once daily delivered with Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium Respimat (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tiotropium high dose once daily delivered with Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Respimat</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tiotropium placebo once daily delivered with Respimat inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Respimat</intervention_name>
    <description>Tiotropium high dose once daily delivered with Respimat inhaler</description>
    <arm_group_label>Tiotropium Respimat (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Respimat</intervention_name>
    <description>Tiotropium placebo once daily delivered with Respimat inhaler</description>
    <arm_group_label>Placebo Respimat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Respimat</intervention_name>
    <description>Tiotropium low dose once daily delivered with Respimat inhaler</description>
    <arm_group_label>Tiotropium Respimat (low dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. All patients including the patients under age (under 20 years old) must sign and date
             an Informed Consent Form consistent with ICH-GCP guidelines and Good Clinical Practice
             (GCP) prior to participation in the trial [i.e. prior to any trial procedures,
             including any pre-trial washout of medications and medication restrictions for
             pulmonary function test (PFT) at Visit 1]. Regarding patients under age, a guardian or
             a legally authorised representative must also sign and date an Informed Consent Form.

          2. Male or female outpatients aged at least 18 years but not more than 75 years at Visit
             0.

          3. All patients must have at least a 12-week history of asthma at the time of enrolment
             (Visit 0) into the trial. The diagnosis should be confirmed at Visit 1 by fulfilling
             inclusion criterion 5.

          4. The initial diagnosis of asthma must have been made before the patient's age of 40.

          5. The diagnosis of asthma has to be confirmed at Visit 1 with a bronchodilator
             reversibility (15-30 minutes after 400 µg salbutamol) resulting in a Forced Expiratory
             Volume in one second (FEV1) increase of at least 12% and at least 200 mL .

          6. All patients must have been on maintenance treatment with a medium, stable dose of
             inhaled corticosteroids (ICS) [alone or in a fixed combination with a Long-acting
             beta-adrenergic (LABA)] for at least 4 weeks prior to Visit 1.

          7. All patients must be symptomatic at Visit 1 (screening) and prior to randomisation at
             Visit 2 as defined by an Asthma Control Questionnaire (ACQ) mean score of at least
             1.5.

          8. All patients must have a pre-bronchodilator FEV1 at least 60% and less than or equal
             to 90% of predicted normal at Visit 1.

          9. Patients must be never-smokers or ex-smokers who stopped smoking at least one year (52
             weeks) prior to enrolment (Visit 0) and who have a smoking history of less than 10
             pack years.

         10. Patients must be able to use the Respimat inhaler correctly, which is judged at the
             discretion of the investigator..

         11. Patients must be able to perform all trial related procedures including technically
             acceptable PFTs and use of electronic diary (eDiary)/peak flow meter, which is judged
             at the discretion of the investigator.

        Exclusion criteria:

          1. Patients with a significant disease other than asthma. A significant disease is
             defined as a disease which, in the opinion of the investigator, may (i) put the
             patient at risk because of participation in the trial, or (ii) influence the results
             of the trial, or (iii) cause concern regarding the patient's ability to participate in
             the trial.

          2. Patients with a clinically relevant abnormal screening (Visit 1) haematology or blood
             chemistry if the abnormality defines a significant disease as defined in exclusion
             criterion no 1.

          3. Patients with a recent history (i.e. 6 months or less) of myocardial infarction prior
             to Visit 0.

          4. Patients who have been hospitalised for cardiac failure during the past year prior to
             Visit 0.

          5. Patients with any unstable or life-threatening cardiac arrhythmia or cardiac
             arrhythmia requiring intervention or a change in drug therapy within the past year
             prior to Visit 0.

          6. Patients with lung diseases other than asthma (e.g. COPD).

          7. Patients with known active tuberculosis.

          8. Patients with malignancy and/or patients who have undergone resection, radiation
             therapy or chemotherapy for malignancy within the last 5 years prior to Visit 0.
             Patients with treated basal cell carcinoma are allowed.

          9. Patients who have undergone thoracotomy with pulmonary resection. Patients with a
             history of thoracotomy for other reasons should be evaluated as per exclusion
             criterion no. 1.

         10. Patients with significant alcohol or drug abuse, which is judged at the discretion of
             the investigator, within the past 2 years prior to Visit 0.

         11. Patients with known hypersensitivity to anticholinergic drugs, benzalkonium chloride
             (BAC), ethylenediaminetetraacetic acid (EDTA), or any other components of the study
             medication delivery systems.

         12. Pregnant or nursing women.

         13. Women of childbearing potential not using a highly effective method of birth control.

         14. Patients who have taken an investigational drug within 4 weeks prior to Visit 1.

         15. Patients who have been treated with beta-blocker medication within four weeks prior to
             Visit 1 and/or during the screening period. Topical cardio-selective beta-blocker eye
             medications for non-narrow angle glaucoma are allowed.

         16. Patients who have been treated with the long-acting anticholinergic tiotropium
             (Spiriva) within four weeks prior to Visit 1 and/or during the screening period.

         17. Patients who have been treated with oral beta-adrenergics within four weeks prior to
             Visit 1 and/or during the Screening period.

         18. Patients who have been treated with systemic corticosteroids within four weeks prior
             to Visit 1 and/or during the screening period.

         19. Patients who have been treated with anti-IgE antibodies, e.g. omalizumab (Xolair®),
             within 6 months prior to Visit 1 and/or during the screening period.

         20. Patients who have been treated with other non-approved and according to international
             guidelines not recommended &quot;experimental&quot; drugs for routine asthma therapy within four
             weeks prior to Visit 1 and/or during the screening period.

         21. Patients with any asthma exacerbation or any respiratory tract infection in the four
             weeks prior to Visit 1 and/or during the screening period.

         22. Patients who are currently participating in another trial.

         23. Patients with narrow-angle glaucoma and/or micturition disorder due to prostatic
             hyperplasia.

         24. Patients with below 80% of the eDiary completion compliance on Visit 2 (diary
             compliance of at least 80% is required).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>205.464.81020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Asahikawa, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atsugi, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chigasaki, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chino, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edogawa-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fujisawa, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hanno, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Himeji, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Himeji, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Himeji, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hino, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hiroshima, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hitachinaka, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iizuka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Itabashi-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaga, Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kagoshima, Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kamogawa, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kisarazu, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kitakyusyu,Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiyose, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kochi, Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kodaira, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koshigaya, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kurashiki, Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kure, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maebashi, Gumma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsue, Shimane</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minato-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Obihiro, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Obihiro, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oita, Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oita, Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saga, Saga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sendai, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Setagaya-Ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Setagaya-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toon, Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokosuka, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.464.81032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>April 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2011</study_first_posted>
  <results_first_submitted>April 22, 2014</results_first_submitted>
  <results_first_submitted_qc>June 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 4, 2014</results_first_posted>
  <last_update_submitted>June 4, 2014</last_update_submitted>
  <last_update_submitted_qc>June 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Respimat</title>
          <description>Placebo Respimat: Tiotropium placebo once daily delivered with Respimat inhaler</description>
        </group>
        <group group_id="P2">
          <title>Tiotropium Respimat (2.5 µg)</title>
          <description>Tiotropium Respimat: Tiotropium 2.5 µg once daily delivered with Respimat inhaler</description>
        </group>
        <group group_id="P3">
          <title>Tiotropium Respimat (5 μg)</title>
          <description>Tiotropium Respimat: Tiotropium 5 μg once daily delivered with Respimat inhaler</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="106"/>
                <participants group_id="P3" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Respimat</title>
          <description>Placebo Respimat: Tiotropium placebo once daily delivered with Respimat inhaler</description>
        </group>
        <group group_id="B2">
          <title>Tiotropium Respimat (2.5 µg)</title>
          <description>Tiotropium Respimat: Tiotropium 2.5 µg once daily delivered with Respimat inhaler</description>
        </group>
        <group group_id="B3">
          <title>Tiotropium Respimat (5 μg)</title>
          <description>Tiotropium Respimat: Tiotropium 5 μg once daily delivered with Respimat inhaler</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="114"/>
            <count group_id="B3" value="114"/>
            <count group_id="B4" value="285"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.8" spread="13.0"/>
                    <measurement group_id="B2" value="44.7" spread="12.1"/>
                    <measurement group_id="B3" value="42.6" spread="12.8"/>
                    <measurement group_id="B4" value="44.5" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Drug-related Adverse Events</title>
        <description>The primary endpoint is the number of patients with drug-related adverse events</description>
        <time_frame>after the first dose of trial medication and within 30 days after the last dose of trial medication, up to 409</time_frame>
        <population>Treated set: all randomised patients who received at least 1 dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Placebo Respimat: Tiotropium placebo once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat (2.5 µg)</title>
            <description>Tiotropium Respimat: Tiotropium 2.5 µg once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat (5 μg)</title>
            <description>Tiotropium Respimat: Tiotropium 5 μg once daily delivered with Respimat inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Drug-related Adverse Events</title>
          <description>The primary endpoint is the number of patients with drug-related adverse events</description>
          <population>Treated set: all randomised patients who received at least 1 dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response</title>
        <description>Trough FEV1 response was defined as change from baseline at week 52</description>
        <time_frame>baseline and week 52</time_frame>
        <population>Full analysis set: all patients of the treated set for which baseline and at least 1 post-baseline efficacy measurement were available</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Placebo Respimat: Tiotropium placebo once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat (2.5 µg)</title>
            <description>Tiotropium Respimat: Tiotropium 2.5 µg once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat (5 μg)</title>
            <description>Tiotropium Respimat: Tiotropium 5 μg once daily delivered with Respimat inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response</title>
          <description>Trough FEV1 response was defined as change from baseline at week 52</description>
          <population>Full analysis set: all patients of the treated set for which baseline and at least 1 post-baseline efficacy measurement were available</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.075" spread="0.039"/>
                    <measurement group_id="O2" value="0.087" spread="0.027"/>
                    <measurement group_id="O3" value="0.187" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as Tiotropium 2.5 µg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7971</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusted for treatment, week, baseline, treatment*week and baseline*week</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.012</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.082</ci_lower_limit>
            <ci_upper_limit>0.106</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as Tiotropium 5 μg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0203</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusted for treatment, week, baseline, treatment*week and baseline*week</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.112</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.018</ci_lower_limit>
            <ci_upper_limit>0.207</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response</title>
        <description>Trough FVC response was defined as change from baseline at week 52</description>
        <time_frame>baseline and week 52</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Placebo Respimat: Tiotropium placebo once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat (2.5 µg)</title>
            <description>Tiotropium Respimat: Tiotropium 2.5 µg once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat (5 μg)</title>
            <description>Tiotropium Respimat: Tiotropium 5 μg once daily delivered with Respimat inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response</title>
          <description>Trough FVC response was defined as change from baseline at week 52</description>
          <population>Full analysis set</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.122" spread="0.044"/>
                    <measurement group_id="O2" value="0.085" spread="0.030"/>
                    <measurement group_id="O3" value="0.204" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as Tiotropium 2.5 µg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4944</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusted for treatment, week, baseline, treatment*week and baseline*week</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.037</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.141</ci_lower_limit>
            <ci_upper_limit>0.068</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as Tiotropium 5 μg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1270</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusted for treatment, week, baseline, treatment*week and baseline*week</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.082</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.054</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.023</ci_lower_limit>
            <ci_upper_limit>0.188</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough PEF Response</title>
        <description>Trough PEF response was defined as change from baseline at week 52</description>
        <time_frame>baseline and week 52</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Placebo Respimat: Tiotropium placebo once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat (2.5 µg)</title>
            <description>Tiotropium Respimat: Tiotropium 2.5 µg once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat (5 μg)</title>
            <description>Tiotropium Respimat: Tiotropium 5 μg once daily delivered with Respimat inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Trough PEF Response</title>
          <description>Trough PEF response was defined as change from baseline at week 52</description>
          <population>Full analysis set</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.078" spread="10.119"/>
                    <measurement group_id="O2" value="35.576" spread="6.917"/>
                    <measurement group_id="O3" value="69.254" spread="7.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as Tiotropium 2.5 µg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9677</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusted for treatment, week, baseline, treatment*week and baseline*week</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.498</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.282</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.634</ci_lower_limit>
            <ci_upper_limit>24.630</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as Tiotropium Respimat 5 μg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0058</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusted for treatment, week, baseline, treatment*week and baseline*week</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>34.176</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.346</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.919</ci_lower_limit>
            <ci_upper_limit>58.432</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean PEFam Response</title>
        <description>Weekly mean PEFam response was defined as change from baseline at week 52</description>
        <time_frame>baseline and week 52</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Placebo Respimat: Tiotropium placebo once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat (2.5 µg)</title>
            <description>Tiotropium Respimat: Tiotropium 2.5 µg once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat (5 μg)</title>
            <description>Tiotropium Respimat: Tiotropium 5 μg once daily delivered with Respimat inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean PEFam Response</title>
          <description>Weekly mean PEFam response was defined as change from baseline at week 52</description>
          <population>Full analysis set</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.288" spread="7.554"/>
                    <measurement group_id="O2" value="10.934" spread="5.231"/>
                    <measurement group_id="O3" value="8.504" spread="5.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as Tiotropium 2.5 µg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3468</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusted for treatment, week, baseline, treatment*week and baseline*week</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.646</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.182</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.388</ci_lower_limit>
            <ci_upper_limit>26.680</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as Tiotropium 5 μg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5013</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusted for treatment, week, baseline, treatment*week and baseline*week</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.216</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.238</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.927</ci_lower_limit>
            <ci_upper_limit>24.359</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean PEFpm Response</title>
        <description>Weekly mean PEFpm response was defined as change from baseline at week 52</description>
        <time_frame>baseline and week 52</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Placebo Respimat: Tiotropium placebo once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat (2.5 µg)</title>
            <description>Tiotropium Respimat: Tiotropium 2.5 µg once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat (5 μg)</title>
            <description>Tiotropium Respimat: Tiotropium 5 μg once daily delivered with Respimat inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean PEFpm Response</title>
          <description>Weekly mean PEFpm response was defined as change from baseline at week 52</description>
          <population>Full analysis set</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.357" spread="7.566"/>
                    <measurement group_id="O2" value="1.101" spread="5.239"/>
                    <measurement group_id="O3" value="6.041" spread="5.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as Tiotropium 2.5 µg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2132</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusted for treatment, week, baseline, treatment*week and baseline*week</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.458</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.196</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.601</ci_lower_limit>
            <ci_upper_limit>29.517</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as Tiotropium 5 μg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0766</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusted for treatment, week, baseline, treatment*week and baseline*week</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>16.398</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.245</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.759</ci_lower_limit>
            <ci_upper_limit>34.555</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean PEF Variability Response</title>
        <description>Weekly mean PEF variability response was defined as change from baseline at week 52.
The PEF variability is the absolute difference between morning and evening PEF value, divided by their mean, expressed as a percent. Response was defined as change from baseline.</description>
        <time_frame>baseline and week 52</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Placebo Respimat: Tiotropium placebo once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat (2.5 µg)</title>
            <description>Tiotropium Respimat: Tiotropium 2.5 µg once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat (5 μg)</title>
            <description>Tiotropium Respimat: Tiotropium 5 μg once daily delivered with Respimat inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean PEF Variability Response</title>
          <description>Weekly mean PEF variability response was defined as change from baseline at week 52.
The PEF variability is the absolute difference between morning and evening PEF value, divided by their mean, expressed as a percent. Response was defined as change from baseline.</description>
          <population>Full analysis set</population>
          <units>percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.367" spread="0.851"/>
                    <measurement group_id="O2" value="-0.968" spread="0.595"/>
                    <measurement group_id="O3" value="0.197" spread="0.595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as Tiotropium 2.5 µg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5629</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusted for treatment, week, baseline, treatment*week and baseline*week</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.601</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.637</ci_lower_limit>
            <ci_upper_limit>1.436</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as Tiotropium 5 μg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5871</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusted for treatment, week, baseline, treatment*week and baseline*week</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.564</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.473</ci_lower_limit>
            <ci_upper_limit>2.601</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Number of Puffs of Rescue Medication During the Whole Day (Response)</title>
        <description>Response of weekly mean number of puffs of rescue medication during the whole day at week 52. Response was defined as change from baseline.</description>
        <time_frame>baseline and week 52</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Placebo Respimat: Tiotropium placebo once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat (2.5 µg)</title>
            <description>Tiotropium Respimat: Tiotropium 2.5 µg once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat (5 μg)</title>
            <description>Tiotropium Respimat: Tiotropium 5 μg once daily delivered with Respimat inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Number of Puffs of Rescue Medication During the Whole Day (Response)</title>
          <description>Response of weekly mean number of puffs of rescue medication during the whole day at week 52. Response was defined as change from baseline.</description>
          <population>Full analysis set</population>
          <units>Puffs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.77"/>
                    <measurement group_id="O2" value="-0.29" spread="1.01"/>
                    <measurement group_id="O3" value="-0.22" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Score of Asthma Symptoms in the Morning (Response)</title>
        <description>Response of weekly mean score of asthma symptoms in the morning at week 52. Response was defined as change from baseline.
5-point verbal rating scale, with answer 1 representing no impairment at all and answer 5 representing the greatest impairment.</description>
        <time_frame>baseline and week 52</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Placebo Respimat: Tiotropium placebo once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat (2.5 µg)</title>
            <description>Tiotropium Respimat: Tiotropium 2.5 µg once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat (5 μg)</title>
            <description>Tiotropium Respimat: Tiotropium 5 μg once daily delivered with Respimat inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Score of Asthma Symptoms in the Morning (Response)</title>
          <description>Response of weekly mean score of asthma symptoms in the morning at week 52. Response was defined as change from baseline.
5-point verbal rating scale, with answer 1 representing no impairment at all and answer 5 representing the greatest impairment.</description>
          <population>Full analysis set</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.43"/>
                    <measurement group_id="O2" value="-0.14" spread="0.49"/>
                    <measurement group_id="O3" value="-0.21" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Score of Asthma Symptoms During the Day (Response)</title>
        <description>Response of weekly mean score of asthma symptoms during the day at week 52. Response was defined as change from baseline.
5-point verbal rating scale, with answer 1 representing no impairment at all and answer 5 representing the greatest impairment.</description>
        <time_frame>baseline and week 52</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Placebo Respimat: Tiotropium placebo once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat (2.5 µg)</title>
            <description>Tiotropium Respimat: Tiotropium 2.5 µg once daily delivered with Respimat inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat (5 μg)</title>
            <description>Tiotropium Respimat: Tiotropium 5 μg once daily delivered with Respimat inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Score of Asthma Symptoms During the Day (Response)</title>
          <description>Response of weekly mean score of asthma symptoms during the day at week 52. Response was defined as change from baseline.
5-point verbal rating scale, with answer 1 representing no impairment at all and answer 5 representing the greatest impairment.</description>
          <population>Full analysis set</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.35"/>
                    <measurement group_id="O2" value="-0.15" spread="0.48"/>
                    <measurement group_id="O3" value="-0.17" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>after the first dose of trial medication and within 30 days after the last dose of trial medication, up to 409 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Respimat</title>
          <description>Placebo Respimat: Tiotropium placebo once daily delivered with Respimat inhaler</description>
        </group>
        <group group_id="E2">
          <title>Tiotropium Respimat (2.5 µg)</title>
          <description>Tiotropium Respimat: Tiotropium 2.5 µg once daily delivered with Respimat inhaler</description>
        </group>
        <group group_id="E3">
          <title>Tiotropium Respimat (5 μg)</title>
          <description>Tiotropium Respimat: Tiotropium 5 μg once daily delivered with Respimat inhaler</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mesenteric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Oral papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="101" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Peak expiratory flow rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

